Krajina: Spojené štáty
Jazyk: angličtina
Zdroj: NLM (National Library of Medicine)
Cefoxitin Sodium (UNII: Q68050H03T) (Cefoxitin - UNII:6OEV9DX57Y)
Sagent Pharmaceuticals
Cefoxitin Sodium
Cefoxitin 10 g
INTRAVENOUS
PRESCRIPTION DRUG
Cefoxitin for Injection, USP is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections , including pneumonia and lung abscess, caused by Streptococcus pneumoniae , other streptococci (excluding enterococci, e.g., Enterococcus faecalis [formerly Streptococcus faecalis ]), Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli , Klebsiella species, Haemophilus influenzae, and Bacteroides species. (2) Urinary tract infections caused by Escherichia coli , Klebsiella species, Proteus mirabilis , Morganella morganii , Proteus vulgaris and Providencia species (including P. rettgeri ). (3) Intra-abdominal infections, including peritonitis and intra-abdominal abscess, caused by Escherichia coli , Klebsiella species, Bacteroides species including Bacteroides fragilis , and Clostridium species. (4) Gynecological infections, including endometritis, pelvi
Cefoxitin for Injection, USP is a dry white to off-white powder supplied in pharmacy bulk package bottles containing cefoxitin sodium as follows: Cefoxitin for Injection, USP is also available in conventional vials containing cefoxitin sodium as follows: Store dry powder between 2° to 25°C (36° to 77°F). Avoid exposure to temperatures above 50°C. The dry material as well as solutions tend to darken, depending on storage conditions; product potency, however, is not adversely affected. Sterile, Nonpyrogenic, Preservative-free. The container closure is not made with natural rubber latex.
Abbreviated New Drug Application
CEFOXITIN- CEFOXITIN INJECTION, POWDER, FOR SOLUTION SAGENT PHARMACEUTICALS ---------- CEFOXITIN FOR INJECTION, USP (FOR INTRAVENOUS USE) PHARMACY BULK PACKAGE – NOT FOR DIRECT INFUSION SAGENT Rx only RECONSTITUTED BULK SOLUTION SHOULD NOT BE USED FOR DIRECT INFUSION. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefoxitin for Injection, USP and other antibacterial drugs, Cefoxitin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. DESCRIPTION Cefoxitin for Injection, USP contains cefoxitin sodium a semi-synthetic, broad-spectrum cephalosporin antibiotic for parenteral administration. It is derived from cephalosporin C, which is produced by _Cephalosporium Acremonium_. Its chemical name is sodium (6_R_, 7_S_)-3-(hydroxymethyl)-7-methoxy-8- oxo-7-[2-(2-thienyl)acetamido]-5-thia-1-azabicyclo [4.2.0]oct-2-ene-2-carboxylate carbamate (ester). The molecular formula is C H N NaO S , and the structural formula is: Cefoxitin for Injection, USP is supplied as a dry powder in vials and contains approximately 53.8 mg (2.3 milliequivalents) of sodium per gram of cefoxitin activity. Solutions of Cefoxitin for Injection, USP range from colorless to light amber in color. The pH of freshly constituted solutions usually ranges from 4.2 to 7. Each pharmacy bulk package bottle contains sterile cefoxitin sodium, USP equivalent to 10 g of cefoxitin and is intended for intravenous infusion only. A pharmacy bulk package is a container of a sterile preparation for parenteral use that contains many single doses. The contents are intended for use in a pharmacy admixture service and are restricted to the preparation of admixtures for intravenous infusion. FURTHER DILUTION IS REQUIRED BEFORE USE. RECONSTITUTED BULK SOLUTION SHOULD NOT BE USED FOR DIRECT INFUSION. RECONSTITUTED STOCK SOLUTION MUST BE TRANSFERRED AND FURTHER DILUTED FOR I.V. INFUSION. CLINICAL PHARMACOLOGY CLINICAL PHARMACOLOGY Following an intravenous Prečítajte si celý dokument